- Wellcare (NYSE:WCG) initiated with Outperform rating and $200 (15% upside) price target by Cowen and Company.
- Altimmune (NASDAQ:ALT) initiated with Overweight rating and $6 (164% upside) price target by Piper Jaffray.
- Almost Family (NASDAQ:AFAM) initiated with Neutral rating and $54 (7% upside) price target by JPMorgan (NYSE:JPM).
- Onconova Therapeutics (NASDAQ:ONTX) initiated with Buy rating and $6 (243% upside) by H.C. Wainwright citing optimism over new Phase 3 study of rigosertib in MDS. Topline data expected in H1 2018.
- Johnson & Johnson (NYSE:JNJ) upgraded to Outperform by Wells Fargo (NYSE:WFC). Shares up 1% premarket.
- MannKind (NASDAQ:MNKD) price target raised to $7 (32% upside) by Maxim Group. Shares up 4% premarket.
- Humana (NYSE:HUM) downgraded to Neutral with a $253 (2% upside) price target by JPMorgan.
- DaVita (NYSE:DVA) downgraded to Underweight by JPMorgan.
- Medtronic (NYSE:MDT) downgraded to Market Perform by Wells Fargo.
- Hologic (NASDAQ:HOLX) price target lowered to $45 from $48 by Stilel.
- Now read: Medtronic Is Not A Replacement For Johnson & Johnson
Original article